Article
Biochemistry & Molecular Biology
Fotian Xie, Yuanming Zhong, Dongmei Wang, Kwok Fai So, Jia Xiao, Yi Lv
Summary: This study found that metformin can protect against lipid formation in ALD by activating the LKB1/AMPK/ACC axis. This research is important for understanding the lipid metabolism mechanisms in ALD and developing therapeutic strategies for ALD.
MOLECULAR BIOLOGY REPORTS
(2022)
Article
Biochemistry & Molecular Biology
Jan Pencik, Cecile Philippe, Michaela Schlederer, Emine Atas, Matteo Pecoraro, Sandra Grund-Groeschke, Wen (Jess) Li, Amanda Tracz, Isabel Heidegger, Sabine Lagger, Karolina Trachtova, Monika Oberhuber, Ellen Heitzer, Osman Aksoy, Heidi A. Neubauer, Bettina Wingelhofer, Anna Orlova, Nadine Witzeneder, Thomas Dillinger, Elisa Redl, Georg Greiner, David D'Andrea, Johnny R. Ostman, Simone Tangermann, Ivana Hermanova, Georg Schaefer, Felix Sternberg, Elena E. Pohl, Christina Sternberg, Adam Varady, Jaqueline Horvath, Dagmar Stoiber, Tim I. Malcolm, Suzanne D. Turner, Eileen E. Parkes, Brigitte Hantusch, Gerda Egger, Stefan Rose-John, Valeria Poli, Suneil Jain, Chris W. D. Armstrong, Gregor Hoermann, Vincent Goffin, Fritz Aberger, Richard Moriggl, Arkaitz Carracedo, Cathal McKinney, Richard D. Kennedy, Helmut Klocker, Michael R. Speicher, Dean G. Tang, Ali A. Moazzami, David M. Heery, Marcus Hacker, Lukas Kenner
Summary: PTEN and STAT3 are frequently co-deleted genes in metastatic prostate cancer (mPCa). STAT3 controls mPCa through the LKB1/pAMPK/mTORC1/CREB signaling pathway, and metformin can inhibit mPCa growth.
Review
Chemistry, Medicinal
Sarah J. Skuli, Safwan Alomari, Hallie Gaitsch, A'ishah Bakayoko, Nicolas Skuli, Betty M. Tyler
Summary: Metformin, as a drug, not only reduces the risk of cancer in type 2 diabetics but also inhibits cell growth in various cancers. However, its mechanism of action in cancer cells and its effect on cancer metabolism are still unclear.
Review
Pharmacology & Pharmacy
Xuewen Wang, Ziwei Liang, Hong Xiang, Yanqiu Li, Shuhua Chen, Hongwei Lu
Summary: LKB1 plays a crucial role in regulating macrophage functions in atherosclerosis, including influencing lipid metabolism, inflammation, endoplasmic reticulum stress, and autophagy. Decreased expression of LKB1 exacerbates vascular injury and foam cell formation in atherosclerosis.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Cell Biology
Mohammed Bourouh, Paola A. Marignani
Summary: Liver kinase B1 (LKB1) is a crucial tumor suppressor kinase that plays a role in various malignancies. It inhibits the growth and division of cancer cells by regulating metabolic pathways. Loss of LKB1 leads to metabolic reprogramming and promotes malignant growth of cancer cells.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Medicine, Research & Experimental
Ali Molaei, Emad Molaei, Hamidreza Sadeghnia, Wallace Hayes, Gholamreza Karimi
Summary: Cardiovascular diseases are the leading cause of morbidity and mortality worldwide, and liver kinase B1 (LKB1) plays a crucial role in the heart. LKB1 activity is associated with improved cardiac function and cardioprotective effects. Activation of the LKB1 signaling pathway offers potential for the prevention and treatment of heart diseases.
Article
Pharmacology & Pharmacy
Belen G. Sanchez, Alicia Bort, Jose M. Mora-Rodriguez, Ines Diaz-Laviada
Summary: Capsaicin activates AMP-activated kinase (AMPK) and induces cell death in LKB1-expressing prostate cancer cells. This effect is dependent on LKB1 and TRPV1, suggesting that capsaicin may be a potential chemotherapeutic option for prostate tumors.
Article
Pharmacology & Pharmacy
Khoa Nguyen, Katherine Hebert, Emily McConnell, Nicole Cullen, Thomas Cheng, Susanna Awoyode, Elizabeth Martin, Weina Chen, Tong Wu, Suresh K. Alahari, Reza Izadpanah, Bridgette M. Collins-Burow, Sean B. Lee, David H. Drewry, Matthew E. Burow
Summary: The liver is an important organ involved in biological functions such as digestion, nutrient storage, and detoxification. It plays an active role in regulating metabolism and is susceptible to hepatocellular carcinoma, which is often associated with chronic inflammation. LKB1 signaling has been found to regulate cellular metabolism and has a tumor suppressive role in many cancers. Using the KMPlotter database, this review correlates RNA levels of LKB1 signaling genes with hepatocellular carcinoma patient survival outcomes and identifies potential biomarkers for clinical use.
PHARMACOLOGICAL RESEARCH
(2023)
Article
Oncology
Chunyang Chen, He Wang, Xinyu Geng, Dongze Zhang, Zhengyu Zhu, Guangbo Zhang, Jianquan Hou
Summary: This study confirmed the inhibitory effect of metformin on prostate cancer cell lines, with mechanisms involving autophagy and cell cycle arrest at G0/G1 phase. Metformin induced AMPK activation, promoted LC3II expression, and down-regulated p62/SQSTM1 expression. Animal experiments demonstrated that metformin reduced tumor volume, upregulated p-AMPK (Thr172) and LC3B, and downregulated Ki-67 levels without abnormal biochemical indicators.
CANCER CELL INTERNATIONAL
(2021)
Article
Biochemistry & Molecular Biology
Seung Bae Rho, Hyun Jung Byun, Boh-Ram Kim, Chang Hoon Lee
Summary: Metformin has anti-proliferative effects in cervical cancer cells, but not in endometrial cancer cells. This difference may be related to the expression of the LKB1 gene.
BIOMOLECULES & THERAPEUTICS
(2021)
Article
Biochemistry & Molecular Biology
Jun H. Heo, Sang R. Lee, Seong Lae Jo, Je-Won Ko, Hyo-Jung Kwon, Eui-Ju Hong
Summary: The incidence of non-alcoholic fatty liver disease (NAFLD) increases in males aged >45 years, which indicates that androgens are associated with the development and/or progression of NAFLD, although excess dietary intake is the primary causative factor. Our study demonstrates that testosterone can influence the development of NAFLD by increasing the expression of AMP-activated protein kinase (AMPK) and LKB1 and modulating the AMPK-ACC signaling pathway.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, Research & Experimental
Shuang Qu, Qiao Liao, Cheng Yu, Yue Chen, Hao Luo, Xuewei Xia, Duofen He, Zaicheng Xu, Pedro A. Jose, Zhuxin Li, Wei Eric Wang, Qing Rex Lyu, Chunyu Zeng
Summary: The regenerative potential of cardiomyocytes in adult mammals is limited. This study discovered that liver kinase B1 (LKB1) negatively regulates cardiomyocyte proliferation and identified Yes-associated protein (YAP) as its downstream effector. Moreover, AMPK plays a crucial role in the LKB1-mediated regulation of cardiomyocyte proliferation. These findings suggest the involvement of the LKB1-AMPK-YAP axis in cardiomyocyte proliferation and its potential as a target for cardiac regeneration.
BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES
(2022)
Review
Medicine, Research & Experimental
Guangli Lu, Zhen Wu, Jia Shang, Zhenxing Xie, Chaoran Chen, Chuning Zhang
Summary: Metformin is the first-line option for treating diabetic patients and has various pharmacological actions, including antitumor, anti-aging, and ovarian protection effects. Recent research has shown that autophagy is a crucial mechanism through which metformin exerts its pharmacological actions, although the effects on autophagy remain inconsistent.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Cell Biology
Edward J. Calabrese, Evgenios Agathokleous, Rachna Kapoor, Gaurav Dhawan, Walter J. Kozumbo, Vittorio Calabrese
Summary: Metformin induced hormetic biphasic dose responses across multiple organ systems and cell types, enhancing resilience to chemical stresses through an anti-inflammatory molecular network, thereby delaying the onset and progression of neurodegenerative and chronic diseases.
AGEING RESEARCH REVIEWS
(2021)
Article
Oncology
Lujie Yang, Qin Zhang, Yanli Xiong, Zhaoqian Dang, He Xiao, Qian Chen, Xiaoyan Dai, Lei Zhang, Jianwu Zhu, Dong Wang, Mengxia Li
Summary: This study discovered that apatinib is a direct activator of AMP-activated protein kinase (AMPK), which inhibits de novo fatty acid synthesis in LKB1-mutant NSCLC. The combination of apatinib with exogenous fatty acid restriction shows promise as a treatment method for LKB1-mutant NSCLC. These findings provide a basis for the accurate and combined application of VEGFR-TKIs, including apatinib and anlotinib, in the treatment of LKB1-mutant NSCLC.